BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem. Antimicrob Agents Chemother 2019;63:e01659-18. [PMID: 30397063 DOI: 10.1128/AAC.01659-18] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Gill CM, Asempa TE, Nicolau DP. Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative. Antimicrob Agents Chemother 2020;64:e00594-20. [PMID: 32423959 DOI: 10.1128/AAC.00594-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Luci G, Mattioli F, Falcone M, Di Paolo A. Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors. Antibiotics (Basel) 2021;10:769. [PMID: 34202609 DOI: 10.3390/antibiotics10070769] [Reference Citation Analysis]
3 Peppoloni S, Pericolini E, Colombari B, Pinetti D, Cermelli C, Fini F, Prati F, Caselli E, Blasi E. The β-Lactamase Inhibitor Boronic Acid Derivative SM23 as a New Anti-Pseudomonas aeruginosa Biofilm. Front Microbiol 2020;11:35. [PMID: 32117094 DOI: 10.3389/fmicb.2020.00035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
4 Shields RK, McCreary EK, Marini RV, Kline EG, Jones CE, Hao B, Chen L, Kreiswirth BN, Doi Y, Clancy CJ, Nguyen MH. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clin Infect Dis 2020;71:667-71. [PMID: 31738396 DOI: 10.1093/cid/ciz1131] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 25.0] [Reference Citation Analysis]
5 Wenzler E, Scoble PJ. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam. Infect Dis Ther 2020;9:769-84. [PMID: 33025557 DOI: 10.1007/s40121-020-00344-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Messner K, Vuong B, Tranmer GK. The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry. Pharmaceuticals 2022;15:264. [DOI: 10.3390/ph15030264] [Reference Citation Analysis]
7 Caselli E, Fini F, Introvigne ML, Stucchi M, Taracila MA, Fish ER, Smolen KA, Rather PN, Powers RA, Wallar BJ, Bonomo RA, Prati F. 1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of β-Lactamase Inhibitors against Acinetobacter baumannii Cephalosporinase. ACS Infect Dis 2020;6:1965-75. [PMID: 32502340 DOI: 10.1021/acsinfecdis.0c00254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yang P, Fujimura S, Du Y, Zhang B, Yang L, Kawamura M, Zhang Z, Zhai S. Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics. Antibiotics (Basel) 2021;10:1096. [PMID: 34572677 DOI: 10.3390/antibiotics10091096] [Reference Citation Analysis]
9 Han R, Sun D, Li S, Chen J, Teng M, Yang B, Dong Y, Wang T. Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients. Antibiotics (Basel) 2021;10:993. [PMID: 34439043 DOI: 10.3390/antibiotics10080993] [Reference Citation Analysis]
10 Sabet M, Tarazi Z, Griffith DC. In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2020;64:e01267-20. [PMID: 32839224 DOI: 10.1128/AAC.01267-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA. Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress". Infect Dis Clin North Am 2020;34:773-819. [PMID: 33011051 DOI: 10.1016/j.idc.2020.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
12 Adembri C, Novelli A, Nobili S. Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting-Focus on ICU Patients and Gram-Negative Strains. Antibiotics (Basel) 2020;9:E676. [PMID: 33036190 DOI: 10.3390/antibiotics9100676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bouza E. The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections. J Antimicrob Chemother 2021;76:iv38-45. [PMID: 34849998 DOI: 10.1093/jac/dkab353] [Reference Citation Analysis]
14 Zhou K, Huo M, Ma W, Mi K, Xu X, Algharib SA, Xie S, Huang L. Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion. Pharmaceutics 2021;13:602. [PMID: 33922109 DOI: 10.3390/pharmaceutics13050602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Trang M, Griffith DC, Bhavnani SM, Loutit JS, Dudley MN, Ambrose PG, Rubino CM. Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients. Antimicrob Agents Chemother 2021;65:e0260620. [PMID: 34097490 DOI: 10.1128/AAC.02606-20] [Reference Citation Analysis]
16 Principe L, Lupia T, Andriani L, Campanile F, Carcione D, Corcione S, Rosa FGD, Luzzati R, Stroffolini G, Steyde M, Decorti G, Bella SD. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians. Pharmaceuticals 2022;15:463. [DOI: 10.3390/ph15040463] [Reference Citation Analysis]
17 Mouktaroudi M, Kotsaki A, Giamarellos-Bourboulis EJ. Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae. Expert Rev Anti Infect Ther 2022. [PMID: 35034551 DOI: 10.1080/14787210.2022.2030219] [Reference Citation Analysis]
18 Castanheira M, Doyle TB, Kantro V, Mendes RE, Shortridge D. Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018. Antimicrob Agents Chemother 2020;64:e01951-19. [PMID: 31712207 DOI: 10.1128/AAC.01951-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
19 Davies DT, Leiris S, Zalacain M, Sprynski N, Castandet J, Bousquet J, Lozano C, Llanos A, Alibaud L, Vasa S, Pattipati R, Valige R, Kummari B, Pothukanuri S, De Piano C, Morrissey I, Holden K, Warn P, Marcoccia F, Benvenuti M, Pozzi C, Tassone G, Mangani S, Docquier J, Pallin D, Elliot R, Lemonnier M, Everett M. Discovery of ANT3310 , a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii. J Med Chem 2020;63:15802-20. [DOI: 10.1021/acs.jmedchem.0c01535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
20 Sadouki Z, McHugh TD, Aarnoutse R, Ortiz Canseco J, Darlow C, Hope W, van Ingen J, Longshaw C, Manissero D, Mead A, Pelligand L, Phee L, Readman J, Ruth MM, Standing JF, Stone N, Wey EQ, Kloprogge F. Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. J Antimicrob Chemother 2021:dkab160. [PMID: 34179966 DOI: 10.1093/jac/dkab160] [Reference Citation Analysis]
21 Jorda A, Zeitlinger M. Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review. Clin Pharmacokinet 2020;59:1071-84. [PMID: 32356105 DOI: 10.1007/s40262-020-00892-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
22 Thamilselvan G, Sarveswari HB, Vasudevan S, Stanley A, Shanmugam K, Vairaprakash P, Solomon AP. Development of an Antibiotic Resistance Breaker to Resensitize Drug-Resistant Staphylococcus aureus: In Silico and In Vitro Approach. Front Cell Infect Microbiol 2021;11:700198. [PMID: 34485178 DOI: 10.3389/fcimb.2021.700198] [Reference Citation Analysis]
23 Khan A, Tran TT, Rios R, Hanson B, Shropshire WC, Sun Z, Diaz L, Dinh AQ, Wanger A, Ostrosky-Zeichner L, Palzkill T, Arias CA, Miller WR. Extensively Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United States. Open Forum Infect Dis 2019;6:ofz273. [PMID: 31281867 DOI: 10.1093/ofid/ofz273] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]